BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Shen S, Lin Y, Yuan X, Shen L, Chen J, Chen L, Qin L, Shen B. Biomarker MicroRNAs for Diagnosis, Prognosis and Treatment of Hepatocellular Carcinoma: A Functional Survey and Comparison. Sci Rep. 2016;6:38311. [PMID: 27917899 DOI: 10.1038/srep38311] [Cited by in Crossref: 58] [Cited by in F6Publishing: 64] [Article Influence: 8.3] [Reference Citation Analysis]
Number Citing Articles
1 Grisetti L, Võ NVT, Nguyễn NNQ, Crocè LS, Visintin A, Tiribelli C, Pascut D. MiR-3201 as a Prognostic Blood Biomarker for Curative Treatments in Hepatocellular Carcinoma. Technol Cancer Res Treat 2022;21:15330338221132924. [PMID: 36537076 DOI: 10.1177/15330338221132924] [Reference Citation Analysis]
2 da Silva Freire AK, Furtado de Mendonça Belmont T, Pinto Santiago EJ, Cristina Cordeiro Farias I, Palmeira do Ó K, Soares da Silva A, Richardson Silva Vasconcelos L. Potential role of circulating miR-21 in the diagnosis of hepatocellular carcinoma: a systematic review and meta-analysis. Expert Rev Mol Diagn 2022;22:1037-52. [PMID: 36348568 DOI: 10.1080/14737159.2022.2145189] [Reference Citation Analysis]
3 Gu S, Jiang M, Zhang B. Microcystin-LR in Primary Liver Cancers: An Overview. Toxins 2022;14:715. [DOI: 10.3390/toxins14100715] [Reference Citation Analysis]
4 Han X, Lu J, Chen C, Deng Y, Pan M, Li Q, Wu H, Li Z, Ni B, Pandurangan A. Seven Hub Genes Predict the Prognosis of Hepatocellular Carcinoma and the Corresponding Competitive Endogenous RNA Network. Journal of Oncology 2022;2022:1-14. [DOI: 10.1155/2022/3379330] [Reference Citation Analysis]
5 Cerrito L, Ainora ME, Mosoni C, Borriello R, Gasbarrini A, Zocco MA. Prognostic Role of Molecular and Imaging Biomarkers for Predicting Advanced Hepatocellular Carcinoma Treatment Efficacy. Cancers 2022;14:4647. [DOI: 10.3390/cancers14194647] [Reference Citation Analysis]
6 da Cruz NS, Pasquarelli-do-nascimento G, e Oliveira ACP, Magalhães KG. Inflammasome-Mediated Cytokines: A Key Connection between Obesity-Associated NASH and Liver Cancer Progression. Biomedicines 2022;10:2344. [DOI: 10.3390/biomedicines10102344] [Reference Citation Analysis]
7 Niture S, Tricoli L, Qi Q, Gadi S, Hayes K, Kumar D. MicroRNA-99b-5p targets mTOR/AR axis, induces autophagy and inhibits prostate cancer cell proliferation. TUB 2022;44:107-26. [DOI: 10.3233/tub-211568] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 2.0] [Reference Citation Analysis]
8 Huang E, Ma T, Zhou J, Ma N, Yang W, Liu C, Hou Z, Chen S, de Castria TB, Zeng B, Zong Z, Zhou T. The development and validation of a novel senescence-related long-chain non-coding RNA (lncRNA) signature that predicts prognosis and the tumor microenvironment of patients with hepatocellular carcinoma. Ann Transl Med 2022;10:766. [PMID: 35965795 DOI: 10.21037/atm-22-3348] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
9 Braghini MR, Lo Re O, Romito I, Fernandez-Barrena MG, Barbaro B, Pomella S, Rota R, Vinciguerra M, Avila MA, Alisi A. Epigenetic remodelling in human hepatocellular carcinoma. J Exp Clin Cancer Res 2022;41:107. [PMID: 35331312 DOI: 10.1186/s13046-022-02297-2] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 3.0] [Reference Citation Analysis]
10 Baj J, Bryliński Ł, Woliński F, Granat M, Kostelecka K, Duda P, Flieger J, Teresiński G, Buszewicz G, Furtak-Niczyporuk M, Portincasa P. Biomarkers and Genetic Markers of Hepatocellular Carcinoma and Cholangiocarcinoma-What Do We Already Know. Cancers (Basel) 2022;14:1493. [PMID: 35326644 DOI: 10.3390/cancers14061493] [Cited by in Crossref: 4] [Cited by in F6Publishing: 5] [Article Influence: 4.0] [Reference Citation Analysis]
11 Song S, Bai M, Li X, Gong S, Yang W, Lei C, Tian H, Si M, Hao X, Guo T. Early Predictive Value of Circulating Biomarkers for Sorafenib in Advanced Hepatocellular Carcinoma. Expert Rev Mol Diagn 2022. [PMID: 35234564 DOI: 10.1080/14737159.2022.2049248] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
12 Gumilas NSA, Widodo I, Ratnasari N, Heriyanto DS. Potential relative quantities of miR-122 and miR-150 to differentiate hepatocellular carcinoma from liver cirrhosis. Non-coding RNA Research 2022;7:34-9. [DOI: 10.1016/j.ncrna.2022.01.004] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
13 Ratnasari N, Lestari P, Renovaldi D, Raditya Ningsih J, Qoriansas N, Wardana T, Hakim S, Signa Aini Gumilas N, Indrarti F, Triwikatmani C, Bayupurnama P, Setyo Heriyanto D, Astuti I, Mubarika Harjana S. Potential plasma biomarkers: miRNA-29c, miRNA-21, and miRNA-155 in clinical progression of Hepatocellular Carcinoma patients. PLoS One 2022;17:e0263298. [PMID: 35157721 DOI: 10.1371/journal.pone.0263298] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
14 Canale M, Foschi FG, Andreone P, Ercolani G, Marisi G, Conti F, Vukotic R, Guarneri V, Burgio V, Ratti F, Aldrighetti L, De Cobelli F, Cascinu S, Ulivi P, Casadei-Gardini A. Role of circulating microRNAs to predict hepatocellular carcinoma recurrence in patients treated with radiofrequency ablation or surgery. HPB (Oxford) 2022;24:244-54. [PMID: 34366240 DOI: 10.1016/j.hpb.2021.06.421] [Reference Citation Analysis]
15 Zhao W, Liu X. MiR-3682 promotes the progression of hepatocellular carcinoma (HCC) via inactivating AMPK signaling by targeting ADRA1A. Ann Hepatol 2022;27 Suppl 1:100570. [PMID: 34706275 DOI: 10.1016/j.aohep.2021.100570] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 3.0] [Reference Citation Analysis]
16 Elango S, Veerappan K, Subbiah U. Biofluid Markers Unveiling Cancer Diagnosis and Prognosis: With Special Reference to Oxidative Stress. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects 2022. [DOI: 10.1007/978-981-16-5422-0_279] [Reference Citation Analysis]
17 Elango S, Veerappan K, Subbiah U. Biofluid Markers Unveiling Cancer Diagnosis and Prognosis: With Special Reference to Oxidative Stress. Handbook of Oxidative Stress in Cancer: Therapeutic Aspects 2022. [DOI: 10.1007/978-981-16-1247-3_279-1] [Reference Citation Analysis]
18 Zhang N, Shen H, Huang S, Wang F, Liu H, Xie F, Jiang L, Chen X. LncRNA FGD5-AS1 functions as an oncogene to upregulate GTPBP4 expression by sponging miR-873-5p in hepatocellular carcinoma. Eur J Histochem 2021;65. [PMID: 34783233 DOI: 10.4081/ejh.2021.3300] [Reference Citation Analysis]
19 Zhang C, Zhang Q, Li H, Wu Y. miR-1229-3p as a Prognostic Predictor Facilitates Cell Viability, Migration, and Invasion of Hepatocellular Carcinoma. Horm Metab Res 2021;53:759-66. [PMID: 34740278 DOI: 10.1055/a-1646-8415] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
20 Barrera-Saldaña HA, Fernández-Garza LE, Barrera-Barrera SA. Liquid biopsy in chronic liver disease. Ann Hepatol 2021;20:100197. [PMID: 32444248 DOI: 10.1016/j.aohep.2020.03.008] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 5.0] [Reference Citation Analysis]
21 Zhu H, Liu X. Advances of Tumorigenesis, Diagnosis at Early Stage, and Cellular Immunotherapy in Gastrointestinal Malignancies. Front Oncol 2021;11:666340. [PMID: 34434889 DOI: 10.3389/fonc.2021.666340] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
22 Ding R, Chen T, Zhang Y, Chen X, Zhuang L, Yang Z. HMGCS2 in metabolic pathways was associated with overall survival in hepatocellular carcinoma: A LASSO-derived study. Sci Prog 2021;104:368504211031749. [PMID: 34260294 DOI: 10.1177/00368504211031749] [Cited by in Crossref: 1] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
23 Lee NH, Kim SJ, Hyun J. MicroRNAs Regulating Hippo-YAP Signaling in Liver Cancer. Biomedicines 2021;9:347. [PMID: 33808155 DOI: 10.3390/biomedicines9040347] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 3.0] [Reference Citation Analysis]
24 Hu B, Ma X, Fu P, Sun Q, Tang W, Sun H, Yang Z, Yu M, Zhou J, Fan J, Xu Y. miRNA-mRNA Regulatory Network and Factors Associated with Prediction of Prognosis in Hepatocellular Carcinoma. Genomics Proteomics Bioinformatics 2021:S1672-0229(21)00059-0. [PMID: 33741523 DOI: 10.1016/j.gpb.2021.03.001] [Cited by in Crossref: 8] [Cited by in F6Publishing: 10] [Article Influence: 4.0] [Reference Citation Analysis]
25 Song T, Li L, Wu S, Liu Y, Guo C, Wang W, Dai L, Zhang T, Wu H, Su B. Peripheral Blood Genetic Biomarkers for the Early Diagnosis of Hepatocellular Carcinoma. Front Oncol 2021;11:583714. [PMID: 33777736 DOI: 10.3389/fonc.2021.583714] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
26 Long G, Fang T, Su W, Mi X, Zhou L. The prognostic value of postoperative circulating cell-free DNA in operable hepatocellular carcinoma. Scand J Gastroenterol 2020;55:1441-6. [PMID: 33119422 DOI: 10.1080/00365521.2020.1839127] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 1.7] [Reference Citation Analysis]
27 Zhong D, Lyu X, Fu X, Xie P, Liu M, He F, Huang G. Upregulation of miR-124-3p by Liver X Receptor Inhibits the Growth of Hepatocellular Carcinoma Cells Via Suppressing Cyclin D1 and CDK6. Technol Cancer Res Treat 2020;19:1533033820967473. [PMID: 33073697 DOI: 10.1177/1533033820967473] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
28 Yang J, Cui R, Liu Y. MicroRNA-212-3p inhibits paclitaxel resistance through regulating epithelial-mesenchymal transition, migration and invasion by targeting ZEB2 in human hepatocellular carcinoma. Oncol Lett 2020;20:23. [PMID: 32774496 DOI: 10.3892/ol.2020.11884] [Cited by in Crossref: 5] [Cited by in F6Publishing: 8] [Article Influence: 1.7] [Reference Citation Analysis]
29 Sartorius K, Swadling L, An P, Makarova J, Winkler C, Chuturgoon A, Kramvis A. The Multiple Roles of Hepatitis B Virus X Protein (HBx) Dysregulated MicroRNA in Hepatitis B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) and Immune Pathways. Viruses 2020;12:E746. [PMID: 32664401 DOI: 10.3390/v12070746] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 5.3] [Reference Citation Analysis]
30 Zhang S, Zhou Y, Wang Y, Wang Z, Xiao Q, Zhang Y, Lou Y, Qiu Y, Zhu F. The mechanistic, diagnostic and therapeutic novel nucleic acids for hepatocellular carcinoma emerging in past score years. Brief Bioinform 2021;22:1860-83. [PMID: 32249290 DOI: 10.1093/bib/bbaa023] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 3.0] [Reference Citation Analysis]
31 Zhao P, Cui X, Zhao L, Liu L, Wang D. Overexpression of Growth-Arrest-Specific Transcript 5 Improved Cisplatin Sensitivity in Hepatocellular Carcinoma Through Sponging miR-222. DNA Cell Biol. 2020;39:724-732. [PMID: 32213078 DOI: 10.1089/dna.2019.5282] [Cited by in Crossref: 11] [Cited by in F6Publishing: 10] [Article Influence: 3.7] [Reference Citation Analysis]
32 Sartorius K, Makarova J, Sartorius B, An P, Winkler C, Chuturgoon A, Kramvis A. The Regulatory Role of MicroRNA in Hepatitis-B Virus-Associated Hepatocellular Carcinoma (HBV-HCC) Pathogenesis. Cells 2019;8:E1504. [PMID: 31771261 DOI: 10.3390/cells8121504] [Cited by in Crossref: 37] [Cited by in F6Publishing: 41] [Article Influence: 9.3] [Reference Citation Analysis]
33 Lamichhane SR, Thachil T, Gee H, Milic N. Circulating MicroRNAs as Prognostic Molecular Biomarkers in Human Head and Neck Cancer: A Systematic Review and Meta-Analysis. Dis Markers 2019;2019:8632018. [PMID: 31827646 DOI: 10.1155/2019/8632018] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
34 Dhama K, Latheef SK, Dadar M, Samad HA, Munjal A, Khandia R, Karthik K, Tiwari R, Yatoo MI, Bhatt P, Chakraborty S, Singh KP, Iqbal HMN, Chaicumpa W, Joshi SK. Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values. Front Mol Biosci 2019;6:91. [PMID: 31750312 DOI: 10.3389/fmolb.2019.00091] [Cited by in Crossref: 99] [Cited by in F6Publishing: 103] [Article Influence: 24.8] [Reference Citation Analysis]
35 Dhama K, Latheef SK, Dadar M, Samad HA, Munjal A, Khandia R, Karthik K, Tiwari R, Yatoo MI, Bhatt P, Chakraborty S, Singh KP, Iqbal HMN, Chaicumpa W, Joshi SK. Biomarkers in Stress Related Diseases/Disorders: Diagnostic, Prognostic, and Therapeutic Values. Front Mol Biosci 2019;6:91. [PMID: 31750312 DOI: 10.3389/fmolb.2019.00091] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
36 Liu Z, Dang C, Xing E, Zhao M, Shi L, Sun J. Overexpression of CASC2 Improves Cisplatin Sensitivity in Hepatocellular Carcinoma Through Sponging miR-222. DNA Cell Biol. 2019;38:1366-1373. [PMID: 31633393 DOI: 10.1089/dna.2019.4882] [Cited by in Crossref: 9] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
37 Nasr MA, Salah RA, Abd Elkodous M, Elshenawy SE, El-Badri N. Dysregulated MicroRNA Fingerprints and Methylation Patterns in Hepatocellular Carcinoma, Cancer Stem Cells, and Mesenchymal Stem Cells. Front Cell Dev Biol 2019;7:229. [PMID: 31681762 DOI: 10.3389/fcell.2019.00229] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 3.0] [Reference Citation Analysis]
38 Yang X, Liu L, Zou H, Zheng YW, Wang KP. circZFR promotes cell proliferation and migration by regulating miR-511/AKT1 axis in hepatocellular carcinoma. Dig Liver Dis 2019;51:1446-55. [PMID: 31147216 DOI: 10.1016/j.dld.2019.04.012] [Cited by in Crossref: 31] [Cited by in F6Publishing: 31] [Article Influence: 7.8] [Reference Citation Analysis]
39 Xu X, Tao Y, Niu Y, Wang Z, Zhang C, Yu Y, Ma L. miR-125a-5p inhibits tumorigenesis in hepatocellular carcinoma. Aging (Albany NY) 2019;11:7639-62. [PMID: 31527306 DOI: 10.18632/aging.102276] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 4.0] [Reference Citation Analysis]
40 Qiu H, Zhang G, Song B, Jia J. MicroRNA-548b inhibits proliferation and invasion of hepatocellular carcinoma cells by directly targeting specificity protein 1. Exp Ther Med 2019;18:2332-40. [PMID: 31452716 DOI: 10.3892/etm.2019.7812] [Cited by in Crossref: 5] [Cited by in F6Publishing: 11] [Article Influence: 1.3] [Reference Citation Analysis]
41 Yun Z, Meng F, Jiang P, Yue M, Li S. microRNA-548b suppresses aggressive phenotypes of hepatocellular carcinoma by directly targeting high-mobility group box 1 mRNA. Cancer Manag Res 2019;11:5821-34. [PMID: 31417317 DOI: 10.2147/CMAR.S198615] [Cited by in Crossref: 6] [Cited by in F6Publishing: 7] [Article Influence: 1.5] [Reference Citation Analysis]
42 El-gohary AM, Zeid AE, Ibrahim ME, Dewedar FI, Elzoheiry EA. Serum microRNA 143 as a potential biomarker for the diagnosis of hepatitis C virus-related hepatocellular carcinoma. Egypt J Intern Med 2019;31:214-221. [DOI: 10.4103/ejim.ejim_82_18] [Reference Citation Analysis]
43 Simile MM, Peitta G, Tomasi ML, Brozzetti S, Feo CF, Porcu A, Cigliano A, Calvisi DF, Feo F, Pascale RM. MicroRNA-203 impacts on the growth, aggressiveness and prognosis of hepatocellular carcinoma by targeting MAT2A and MAT2B genes. Oncotarget 2019;10:2835-54. [PMID: 31073374 DOI: 10.18632/oncotarget.26838] [Cited by in Crossref: 14] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
44 Tsuchiya A, Ogawa M, Watanabe T, Takeuchi S, Kojima Y, Watanabe Y, Kimura N, Hayashi K, Yokoyama J, Terai S. Diverse perspectives to address for the future treatment of heterogeneous hepatocellular carcinoma. Heliyon 2019;5:e01325. [PMID: 30911692 DOI: 10.1016/j.heliyon.2019.e01325] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.5] [Reference Citation Analysis]
45 De Stefano F, Chacon E, Turcios L, Marti F, Gedaly R. Novel biomarkers in hepatocellular carcinoma. Dig Liver Dis 2018;50:1115-23. [PMID: 30217732 DOI: 10.1016/j.dld.2018.08.019] [Cited by in Crossref: 71] [Cited by in F6Publishing: 78] [Article Influence: 14.2] [Reference Citation Analysis]
46 Yan HB, Zhang Y, Cen JM, Wang X, Gan BL, Huang JC, Li JY, Song QH, Li SH, Chen G. Expression of microRNA-99a-3p in Prostate Cancer Based on Bioinformatics Data and Meta-Analysis of a Literature Review of 965 Cases. Med Sci Monit 2018;24:4807-22. [PMID: 29997385 DOI: 10.12659/MSM.908057] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.6] [Reference Citation Analysis]
47 Matin F, Jeet V, Moya L, Selth LA, Chambers S, Clements JA, Batra J; Australian Prostate Cancer BioResource. A Plasma Biomarker Panel of Four MicroRNAs for the Diagnosis of Prostate Cancer. Sci Rep 2018;8:6653. [PMID: 29703916 DOI: 10.1038/s41598-018-24424-w] [Cited by in Crossref: 43] [Cited by in F6Publishing: 50] [Article Influence: 8.6] [Reference Citation Analysis]
48 Toraih EA, Ellawindy A, Fala SY, Al Ageeli E, Gouda NS, Fawzy MS, Hosny S. Oncogenic long noncoding RNA MALAT1 and HCV-related hepatocellular carcinoma. Biomed Pharmacother 2018;102:653-69. [PMID: 29604585 DOI: 10.1016/j.biopha.2018.03.105] [Cited by in Crossref: 31] [Cited by in F6Publishing: 30] [Article Influence: 6.2] [Reference Citation Analysis]
49 Rashad NM, El-Shal AS, Shalaby SM, Mohamed SY. Serum miRNA-27a and miRNA-18b as potential predictive biomarkers of hepatitis C virus-associated hepatocellular carcinoma. Mol Cell Biochem 2018;447:125-36. [PMID: 29455432 DOI: 10.1007/s11010-018-3298-8] [Cited by in Crossref: 21] [Cited by in F6Publishing: 20] [Article Influence: 4.2] [Reference Citation Analysis]
50 Xu L, Li T, Ding W, Cao Y, Ge X, Wang Y. Combined seven miRNAs for early hepatocellular carcinoma detection with chronic low-dose exposure to microcystin-LR in mice. Sci Total Environ 2018;628-629:271-81. [PMID: 29438936 DOI: 10.1016/j.scitotenv.2018.02.021] [Cited by in Crossref: 10] [Cited by in F6Publishing: 11] [Article Influence: 2.0] [Reference Citation Analysis]
51 Chen Z, Han Y, Song C, Wei H, Chen Y, Huang K, Li S, Ma D, Wang S, Wang J, Lu Q. Systematic review and meta-analysis of the prognostic significance of microRNAs in cervical cancer. Oncotarget 2018;9:17141-8. [PMID: 29682211 DOI: 10.18632/oncotarget.23839] [Cited by in Crossref: 13] [Cited by in F6Publishing: 15] [Article Influence: 2.2] [Reference Citation Analysis]
52 Du B, Zhang P, Tan Z, Xu J. MiR-1202 suppresses hepatocellular carcinoma cells migration and invasion by targeting cyclin dependent kinase 14. Biomed Pharmacother 2017;96:1246-52. [PMID: 29217161 DOI: 10.1016/j.biopha.2017.11.090] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 2.5] [Reference Citation Analysis]
53 Zhang R, Zhang LJ, Yang ML, Huang LS, Chen G, Feng ZB. Potential role of microRNA‑223‑3p in the tumorigenesis of hepatocellular carcinoma: A comprehensive study based on data mining and bioinformatics. Mol Med Rep 2018;17:2211-28. [PMID: 29207133 DOI: 10.3892/mmr.2017.8167] [Cited by in Crossref: 4] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
54 Wilson CL, Mann DA, Borthwick LA. Epigenetic reprogramming in liver fibrosis and cancer. Adv Drug Deliv Rev 2017;121:124-32. [PMID: 29079534 DOI: 10.1016/j.addr.2017.10.011] [Cited by in Crossref: 43] [Cited by in F6Publishing: 48] [Article Influence: 7.2] [Reference Citation Analysis]
55 Dai M, Chen S, Wei X, Zhu X, Lan F, Dai S, Qin X. Diagnosis, prognosis and bioinformatics analysis of lncRNAs in hepatocellular carcinoma. Oncotarget 2017;8:95799-809. [PMID: 29221168 DOI: 10.18632/oncotarget.21329] [Cited by in Crossref: 30] [Cited by in F6Publishing: 34] [Article Influence: 5.0] [Reference Citation Analysis]
56 Gomez-Cambronero J, Fite K, Miller TE. How miRs and mRNA deadenylases could post-transcriptionally regulate expression of tumor-promoting protein PLD. Adv Biol Regul 2018;68:107-19. [PMID: 28964725 DOI: 10.1016/j.jbior.2017.08.002] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.8] [Reference Citation Analysis]
57 Peng F, Tang H, Liu P, Shen J, Guan X, Xie X, Gao J, Xiong L, Jia L, Chen J, Peng C. Isoliquiritigenin modulates miR-374a/PTEN/Akt axis to suppress breast cancer tumorigenesis and metastasis. Sci Rep 2017;7:9022. [PMID: 28827662 DOI: 10.1038/s41598-017-08422-y] [Cited by in Crossref: 33] [Cited by in F6Publishing: 34] [Article Influence: 5.5] [Reference Citation Analysis]
58 Okajima W, Komatsu S, Ichikawa D, Miyamae M, Ohashi T, Imamura T, Kiuchi J, Nishibeppu K, Arita T, Konishi H, Shiozaki A, Morimura R, Ikoma H, Okamoto K, Otsuji E. Liquid biopsy in patients with hepatocellular carcinoma: Circulating tumor cells and cell-free nucleic acids. World J Gastroenterol 2017; 23(31): 5650-5668 [PMID: 28883691 DOI: 10.3748/wjg.v23.i31.5650] [Cited by in CrossRef: 56] [Cited by in F6Publishing: 60] [Article Influence: 9.3] [Reference Citation Analysis]
59 Cervello M, Augello G, Cusimano A, Emma MR, Balasus D, Azzolina A, Mccubrey JA, Montalto G. Pivotal roles of glycogen synthase-3 in hepatocellular carcinoma. Advances in Biological Regulation 2017;65:59-76. [DOI: 10.1016/j.jbior.2017.06.002] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 5.0] [Reference Citation Analysis]
60 de Conti A, Ortega JF, Tryndyak V, Dreval K, Moreno FS, Rusyn I, Beland FA, Pogribny IP. MicroRNA deregulation in nonalcoholic steatohepatitis-associated liver carcinogenesis. Oncotarget. 2017;8:88517-88528. [PMID: 29179453 DOI: 10.18632/oncotarget.19774] [Cited by in Crossref: 35] [Cited by in F6Publishing: 40] [Article Influence: 5.8] [Reference Citation Analysis]
61 Wang Y, Liu Z, Yao B, Li Q, Wang L, Wang C, Dou C, Xu M, Liu Q, Tu K. Long non-coding RNA CASC2 suppresses epithelial-mesenchymal transition of hepatocellular carcinoma cells through CASC2/miR-367/FBXW7 axis. Mol Cancer. 2017;16:123. [PMID: 28716020 DOI: 10.1186/s12943-017-0702-z] [Cited by in Crossref: 149] [Cited by in F6Publishing: 173] [Article Influence: 24.8] [Reference Citation Analysis]
62 Liu F, Zhang F, Li X, Liu Q, Liu W, Song P, Qiu Z, Dong Y, Xiang H. Prognostic role of miR-17-92 family in human cancers: evaluation of multiple prognostic outcomes. Oncotarget 2017;8:69125-38. [PMID: 28978185 DOI: 10.18632/oncotarget.19096] [Cited by in Crossref: 20] [Cited by in F6Publishing: 21] [Article Influence: 3.3] [Reference Citation Analysis]
63 Shao Y, Liang B, Long F, Jiang SJ. Diagnostic MicroRNA Biomarker Discovery for Non-Small-Cell Lung Cancer Adenocarcinoma by Integrative Bioinformatics Analysis. Biomed Res Int 2017;2017:2563085. [PMID: 28698868 DOI: 10.1155/2017/2563085] [Cited by in Crossref: 14] [Cited by in F6Publishing: 22] [Article Influence: 2.3] [Reference Citation Analysis]
64 Zhao J, Xu T, Wang F, Cai W, Chen L. miR-493-5p suppresses hepatocellular carcinoma cell proliferation through targeting GP73. Biomed Pharmacother 2017;90:744-51. [PMID: 28419971 DOI: 10.1016/j.biopha.2017.04.029] [Cited by in Crossref: 24] [Cited by in F6Publishing: 25] [Article Influence: 4.0] [Reference Citation Analysis]
65 Fang M, Zheng WJ, Yao M, Dong ZZ, Yao DF. Novel specific markers for hepatocellular carcinoma: Perspective on clinical applications. Shijie Huaren Xiaohua Zazhi 2017; 25(10): 865-873 [DOI: 10.11569/wcjd.v25.i10.865] [Cited by in CrossRef: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
66 Lin Y, Chen J, Shen B. Interactions Between Genetics, Lifestyle, and Environmental Factors for Healthcare. Adv Exp Med Biol 2017;1005:167-91. [PMID: 28916933 DOI: 10.1007/978-981-10-5717-5_8] [Cited by in Crossref: 17] [Cited by in F6Publishing: 19] [Article Influence: 2.8] [Reference Citation Analysis]